Skip to main content

Advertisement

SpringerLink
Log in

The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Signal transducer and activator of transcription (STAT) transcription factors family are involved in diverse cellular biological functions. Reports regarding the prognostic impact of STAT3 expression in breast cancer (BC) are variable whether being a factor of poor or good prognosis. Immunohistochemical expression of phospho-STAT3 (pSTAT3) was studied in large series of invasive BC (n = 1270). pSTAT3 and STAT3 were quantified using reverse phase protein array (RPPA) on proteins extracted from macro-dissected FFPE tissues (n = 49 cases). STAT3 gene expression in the METABRIC cohort was also investigated. STAT3 gene expression prognostic impact was externally validated using the online BC gene expression data (n = 26 datasets, 4.177 patients). pSTAT3 was expressed in the nuclei and cytoplasm of invasive BC cells. Nuclear pSTAT3 overexpression was positively associated with smaller tumour size, lower grade, good NPI, negative lymphovascular invasion (LVI), ER+, PgR+, p53−, HER2−, and low Ki67LI and an improved breast cancer-specific survival (BCSS), independently of other factors. On RPPA, the mean pSTAT3 and STAT3 expressions were higher in ER+, PgR+, and smaller size tumours. Higher STAT3 transcripts in the METABRIC cohort were observed in cases with favourable prognostic criteria and as well as improved BCSS within the whole cohort, ER+ cohort with and without hormonal therapy, and ER− cohort including those who did not receive adjuvant chemotherapy. Pooled STAT3 gene expression data in the external validation cohort showed an association with improved patients’ outcome (P < 0.001, HR = 0.84, 95 % CI 0.79–0.90). Results of this study suggest nuclear localisation of pSTAT3 as favourable prognostic marker in invasive BC, results re-enforced by analysis of STAT3 gene expression data. This good prognostic advantage was maintained in patients who received and who did not receive adjuvant therapy. Therefore, STAT3 could have context-dependent molecular roles of in BC, results which warrant further prospective verification in clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Levy DE, Darnell JE Jr (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3(9):651–662

    Article  CAS  PubMed  Google Scholar 

  2. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B (2009) Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 1171:59–76

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Watson CJ, Neoh K (2008) The Stat family of transcription factors have diverse roles in mammary gland development. Semin Cell Dev Biol 19(4):401–406

    Article  CAS  PubMed  Google Scholar 

  4. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE (2005) New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell cycle (Georgetown, Tex), 4(9):1131–1133

  5. Johnston PA, Grandis JR (2011) STAT3 signaling: anticancer strategies and challenges. Mol Interv 11(1):18–26

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D et al (2010) Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res 16(8):2427–2434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chen Y, Wang J, Wang X, Liu X, Li H, Lv Q, Zhu J, Wei B, Tang Y (2013) STAT3, a poor survival predicator, is associated with lymph node metastasis from breast cancer. J Breast Cancer 16(1):40–49

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sonnenblick A, Shriki A, Galun E, Axelrod JH, Daum H, Rottenberg Y, Hamburger T, Mali B, Peretz T (2012) Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis. Clin Transl Oncol 14(3):232–236

    Article  CAS  PubMed  Google Scholar 

  9. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL (2003) Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9(2):594–600

    CAS  PubMed  Google Scholar 

  10. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer J Int du Cancer 116(3):340–350

    Article  CAS  Google Scholar 

  11. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302–2310

    Article  CAS  PubMed  Google Scholar 

  12. Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, Robertson JF, Mitchell MJ, Ball GR, Haybittle JL et al (2007) Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990–1999. Eur J Cancer (Oxford, England: 1990), 43(10):1548–1555

  13. McCarty KS Jr, McCarty KS Sr (1984) Histochemical approaches to steroid receptor analyses. Semin Diagn Pathol 1(4):297–308

    PubMed  Google Scholar 

  14. Aleskandarany MA, Negm OH, Rakha EA, Ahmed MA, Nolan CC, Ball GR, Caldas C, Green AR, Tighe PJ, Ellis IO (2012) TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. Breast Cancer Res Treat 136(2):419–427

    Article  CAS  PubMed  Google Scholar 

  15. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y et al (2012) The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486(7403):346–352

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Jezequel P, Campone M, Gouraud W, Guerin-Charbonnel C, Leux C, Ricolleau G, Campion L (2012) bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat 131(3):765–775

    Article  PubMed  Google Scholar 

  17. Santos CI, Costa-Pereira AP (1816) Signal transducers and activators of transcription-from cytokine signalling to cancer biology. Biochim Biophys Acta 1:38–49

    Google Scholar 

  18. Alvarez JV, Frank DA (2004) Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol Ther 3(11):1045–1050

    Article  CAS  PubMed  Google Scholar 

  19. Hodge DR, Hurt EM, Farrar WL (2005) The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41(16):2502–2512

    Article  CAS  PubMed  Google Scholar 

  20. Clevenger CV (2004) Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 165(5):1449–1460

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Aleskandarany MA, Soria D, Green AR, Nolan C, Diez-Rodriguez M, Ellis IO, Rakha EA (2015) Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. Breast Cancer Res Treat 151(2):325–333

    Article  CAS  PubMed  Google Scholar 

  22. Sonnenblick A, Uziely B, Nechushtan H, Kadouri L, Galun E, Axelrod JH, Katz D, Daum H, Hamburger T, Maly B et al (2013) Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 138(2):407–413

    Article  CAS  PubMed  Google Scholar 

  23. Mao Y, Qu Q, Zhang YZ, Liu JJ, Wang G, Liang Y, Shen KW (2014) The prognosis of signal transducer and activator of transcription 3 expression on breast cancer survival: a meta-analysis and retrospective study. Ann Oncol 25(suppl 1):i14

    Article  Google Scholar 

  24. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, Levy DE, DePinho RA, Bonni A (2008) Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22(4):449–462

    Article  PubMed  PubMed Central  Google Scholar 

  25. Gordziel C, Bratsch J, Moriggl R, Knosel T, Friedrich K (2013) Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. Br J Cancer 109(1):138–146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Li MX, Bi XY, Huang Z, Zhao JJ, Han Y, Li ZY, Zhang YF, Li Y, Chen X, Hu XH et al (2015) Prognostic role of phospho-STAT3 in patients with cancers of the digestive system: a systematic review and meta-analysis. Plos One 10(5):e0127356

    Article  PubMed  PubMed Central  Google Scholar 

  27. Sosonkina N, Starenki D, Park J-I (2014) The role of STAT3 in thyroid cancer. Cancers 6(1):526–544

    Article  PubMed  PubMed Central  Google Scholar 

  28. Xiong H, Du W, Wang JL, Wang YC, Tang JT, Hong J, Fang JY (2012) Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. J Mol Med (Berlin, Germany), 90(9):1037–1046

  29. Huang X, Meng B, Iqbal J, Ding BB, Perry AM, Cao W, Smith LM, Bi C, Jiang C, Greiner TC et al (2013) Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 31(36):4520–4528

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T, Sekine I (2006) Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15(6):1445–1451

    CAS  PubMed  Google Scholar 

  31. Seethala RR, Gooding WE, Handler PN, Collins B, Zhang Q, Siegfried JM, Grandis JR (2008) Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res 14(5):1303–1309

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. de la Iglesia N, Konopka G, Lim KL, Nutt CL, Bromberg JF, Frank DA, Mischel PS, Louis DN, Bonni A (2008) Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci 28(23):5870–5878

    Article  PubMed  PubMed Central  Google Scholar 

  33. Li H, Xiao W, Ma J, Zhang Y, Li R, Ye J, Wang X, Zhong X, Wang S (2014) Dual high expression of STAT3 and cyclinD1 is associated with poor prognosis after curative resection of esophageal squamous cell carcinoma. Int J Clin Exp Pathol 7(11):7989–7998

    PubMed  PubMed Central  Google Scholar 

  34. Kong H, Zhang Q, Zeng Y, Wang H, Wu M, Zheng T, Zeng Y, Shi H (2015) Prognostic significance of STAT3/phosphorylated-STAT3 in tumor: a meta-analysis of literatures. (1940–5901 (Electronic))

  35. Ecker A, Simma O, Hoelbl A, Kenner L, Beug H, Moriggl R, Sexl V (2009) The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. Front Biosci 14:2944–2958

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, NG5 1PB, UK

    Mohammed A. Aleskandarany, Maria Diez-Rodriguez, Christopher C. Nolan, Andrew R. Green, Ian O. Ellis & Emad A. Rakha

  2. Department of Pathology, Faculty of Medicine, Menoufia University, Menoufia, Egypt

    Mohammed A. Aleskandarany & Emad A. Rakha

  3. School of Science & Technology, Nottingham Trent University, Nottingham, UK

    Devika Agarwal & Graham Ball

  4. Division of Immunology, School of Medicine, University of Nottingham, Nottingham, UK

    Ola H. Negm & Patrick J. Tighe

  5. Molecular Diagnostics and Personalised Therapeutics Unit, University of Ha’il, Ha’il, Saudi Arabia

    Ahmed Elmouna, Ibraheem Ashankyty, Edem Nuglozeh & Mohammad F. Fazaludeen

Authors
  1. Mohammed A. Aleskandarany
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Devika Agarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ola H. Negm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Graham Ball
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ahmed Elmouna
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ibraheem Ashankyty
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Edem Nuglozeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mohammad F. Fazaludeen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maria Diez-Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Christopher C. Nolan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Patrick J. Tighe
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Andrew R. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ian O. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Emad A. Rakha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammed A. Aleskandarany.

Ethics declarations

Conflict of interest

All the authors have no conflicts of interest to declare.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aleskandarany, M.A., Agarwal, D., Negm, O.H. et al. The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. Breast Cancer Res Treat 156, 9–20 (2016). https://doi.org/10.1007/s10549-016-3709-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-016-3709-z

Keywords

Search

Navigation